2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Isocitrate Dehydrogenase (IDH)
  5. Isocitrate Dehydrogenase (IDH) Control

Isocitrate Dehydrogenase (IDH) Control

Isocitrate Dehydrogenase (IDH) Isoform Comparison

Isocitrate Dehydrogenase (IDH) Controls (3):

Cat. No. Product Name Effect Purity
  • HY-18767A
    (R,S)-Ivosidenib
    		Control 98.01%
    (R,S)-Ivosidenib ((R,S)-AG-120) is a (R,S)-enantiomer of Ivosidenib (AG-120) with lower activity. Ivosidenib can be used in research on IDH1-mutant cancers.
  • HY-128888B
    (S,R)-GSK321
    		Control 98.62%
    (S,R)-GSK321 is the (S,R)-enantiomer of GSK321 (HY-18948). GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers.
  • HY-123153
    GSK990
    		Control
    GSK990 is an inactive mutant IDH1 inhibitor with no significant inhibitory activity against wild-type or mutant IDH1/IDH2 enzymes. In experiments, GSK990 can serve as an inactive negative control for the IDH1 inhibitor GSK321 (HY-18948). GSK990 is applicable to the research of acute myeloid leukemia.